Agreed. the SAE/AE data give strong indication that the efficacy data will be great. They give p-values in the neighborhood of 0.05 or lower for comparisons that are not even designed for demonstrating efficacy. The primary and secondary outcomes are much better at teasing out efficacy. I'm predicting results that are at least clear and convincing results or even beyond a reasonable doubt. The FDA jury can't help but to convict leronlimab of being effective.